Allena Pharmaceuticals Announces Single-Ascending Doses of ALLN-346 Oral Enzyme Well-Tolerated; Advancing to Phase 1b Multiple-Ascending Dose Study and Phase 2 Proof-of-Concept Trial With Initial Data from Both Studies Expected in Second Half of 2021